CRISPR/Cas9 genome engineering in hematopoietic cells

The development of genome editing tools capable of modifying specific genomic sequences with unprecedented accuracy has opened up a wide range of new possibilities in targeted gene manipulation. In particular, the CRISPR
The development of genome editing tools capable of modifying specific genomic sequences with unprecedented accuracy has opened up a wide range of new possibilities in targeted gene manipulation. In particular, the CRISPR/Cas9 system, a repurposed prokaryotic adaptive immune system, has been widely adopted because of its unmatched simplicity and flexibility.
In this review we discuss achievements and current limitations of CRISPR/Cas9 genome editing in hematopoietic cells with special emphasis on its potential use in ex vivo gene therapy of monogenic blood disorders, HIV and cancer.
show moreshow less

Export metadata

  • Export Bibtex
  • Export RIS
Metadaten
Author:Duran Sürün, Harald von Melchner, Frank Schnütgen
URN:urn:nbn:de:hebis:30:3-514012
DOI:http://dx.doi.org/10.1016/j.ddtec.2018.08.001
ISSN:1740-6749
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=30205879
Parent Title (English):Drug discovery today. Technologies
Publisher:Elsevier
Place of publication:Amsterdam [u.a.]
Contributor(s):Milena Bellin
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/08/25
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2019/10/21
Volume:28
Pagenumber:7
First Page:33
Last Page:39
Note:
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
HeBIS PPN:455688702
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0

$Rev: 11761 $